Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention.
Groupes témoinsMéthodes de recherche
#2
Quel est le rôle d'un groupe témoin ?
Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité.
Groupes témoinsÉvaluation des traitements
#3
Comment choisir un groupe témoin ?
Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité.
Groupes témoinsCritères d'inclusion
#4
Les groupes témoins sont-ils toujours nécessaires ?
Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques.
Groupes témoinsEssais cliniques
Symptômes
2
#1
Les groupes témoins montrent-ils des symptômes ?
Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement.
Groupes témoinsSymptômes
#2
Comment les symptômes sont-ils évalués ?
Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes.
Évaluation des symptômesGroupes témoins
Prévention
2
#1
Les groupes témoins aident-ils à la prévention ?
Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison.
PréventionGroupes témoins
#2
Comment les groupes témoins influencent-ils la prévention ?
Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention.
Mesures préventivesGroupes témoins
Traitements
2
#1
Quel type de traitement est comparé ?
Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin.
Traitements expérimentauxGroupes témoins
#2
Comment les résultats sont-ils mesurés ?
Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes.
Mesure des résultatsGroupes témoins
Complications
2
#1
Les complications sont-elles observées dans les groupes témoins ?
Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental.
ComplicationsGroupes témoins
#2
Comment les complications sont-elles analysées ?
Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité.
Analyse des complicationsGroupes témoins
Facteurs de risque
2
#1
Les groupes témoins aident-ils à identifier des facteurs de risque ?
Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin.
Facteurs de risqueGroupes témoins
#2
Comment les facteurs de risque sont-ils évalués ?
Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes.
Évaluation des facteurs de risqueGroupes témoins
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Groupes témoins : Questions médicales les plus fréquentes",
"headline": "Groupes témoins : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Groupes témoins : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Groupes témoins"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Méthodes",
"url": "https://questionsmedicales.fr/mesh/D008722",
"about": {
"@type": "MedicalCondition",
"name": "Méthodes",
"code": {
"@type": "MedicalCode",
"code": "D008722",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.581"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Groupes témoins",
"alternateName": "Control Groups",
"code": {
"@type": "MedicalCode",
"code": "D035061",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Steger-Hartmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Steger-Hartmann",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Tania Rivera-Hernandez",
"url": "https://questionsmedicales.fr/author/Tania%20Rivera-Hernandez",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark J Walker",
"url": "https://questionsmedicales.fr/author/Mark%20J%20Walker",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark R Davies",
"url": "https://questionsmedicales.fr/author/Mark%20R%20Davies",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia."
}
},
{
"@type": "Person",
"name": "Alexander Gurjanov",
"url": "https://questionsmedicales.fr/author/Alexander%20Gurjanov",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Status of Workers' Health Behavior and the Association between Occupational Characteristics and Health Behavior.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36293597",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph192013021"
}
},
{
"@type": "ScholarlyArticle",
"name": "The effect of retirement on health behaviors.",
"datePublished": "2023-06-20",
"url": "https://questionsmedicales.fr/article/37340536",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/hec.4723"
}
},
{
"@type": "ScholarlyArticle",
"name": "Matching, behavioral economics, and teleological behaviorism: Final cause analysis of substance use and health behavior.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36541360",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jeab.815"
}
},
{
"@type": "ScholarlyArticle",
"name": "Application of behavioral economics for understanding health behaviors among adolescents and young adults.",
"datePublished": "2022-07-05",
"url": "https://questionsmedicales.fr/article/35793607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MOP.0000000000001126"
}
},
{
"@type": "ScholarlyArticle",
"name": "Health literacy and health behaviors of Guinean university students residing in Brazil.",
"datePublished": "2023-10-27",
"url": "https://questionsmedicales.fr/article/37909515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1983-1447.2023.20220295.en"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Méthodes",
"item": "https://questionsmedicales.fr/mesh/D008722"
},
{
"@type": "ListItem",
"position": 4,
"name": "Groupes témoins",
"item": "https://questionsmedicales.fr/mesh/D035061"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Groupes témoins - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Groupes témoins",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Groupes témoins",
"description": "Comment identifier un groupe témoin ?\nQuel est le rôle d'un groupe témoin ?\nComment choisir un groupe témoin ?\nLes groupes témoins sont-ils toujours nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Health+Behavior#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Groupes témoins",
"description": "Les groupes témoins montrent-ils des symptômes ?\nComment les symptômes sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Health+Behavior#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Groupes témoins",
"description": "Les groupes témoins aident-ils à la prévention ?\nComment les groupes témoins influencent-ils la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Health+Behavior#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Groupes témoins",
"description": "Quel type de traitement est comparé ?\nComment les résultats sont-ils mesurés ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Health+Behavior#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Groupes témoins",
"description": "Les complications sont-elles observées dans les groupes témoins ?\nComment les complications sont-elles analysées ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Health+Behavior#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Groupes témoins",
"description": "Les groupes témoins aident-ils à identifier des facteurs de risque ?\nComment les facteurs de risque sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?mesh_terms=Health+Behavior#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un groupe témoin ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention."
}
},
{
"@type": "Question",
"name": "Quel est le rôle d'un groupe témoin ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Comment choisir un groupe témoin ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins sont-ils toujours nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques."
}
},
{
"@type": "Question",
"name": "Les groupes témoins montrent-ils des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à la prévention ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison."
}
},
{
"@type": "Question",
"name": "Comment les groupes témoins influencent-ils la prévention ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention."
}
},
{
"@type": "Question",
"name": "Quel type de traitement est comparé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin."
}
},
{
"@type": "Question",
"name": "Comment les résultats sont-ils mesurés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles observées dans les groupes témoins ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles analysées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à identifier des facteurs de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes."
}
}
]
}
]
}
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
This study investigated differences in unhealthy lifestyle behaviors (ULBs) between workers and nonworkers and demonstrated the association of ULBs with occupational characteristics among workers. Thi...
This paper analyzes the effect of retirement on health behaviors using three nationally representative U.S. datasets. Findings show a decrease in drinking at the intensive margin, particularly for mal...
Howard Rachlin and his contemporaries pioneered basic behavioral science innovations that have been usefully applied to advance understanding of human substance use disorder and related health behavio...
Behavioral economics (BE) concepts have become well studied tools in addressing patient issues, such as weight loss, smoking cessation, and medication adherence. Although predominantly studied in adul...
We identified substantive areas in which BE concepts have been applied in AYA populations (e.g., substance use) and outline how these concepts have been used as a tool to identify individuals at risk ...
BE research holds significant promise as a tool for clinicians and researchers to encourage healthy decision making in AYA populations. Yet, there are opportunities for BE research to expand further i...
To evaluate the health literacy and health behaviors of Guinean university students residing in Brazil....
A cross-sectional, analytical study conducted with 51 Guinean university students residing in Brazil. A health behavior questionnaire and the Test of Functional Health Literacy in Adults - Short versi...
Health literacy was adequate (median=79; IQR=24). Reading comprehension (median=70; IQR=16) of health information was better than numerical comprehension (median=14; IQR=14). Better health literacy pe...
Adequate health literacy of Guinean university students was associated with mostly healthy behaviors, except for screen time and consumption of fatty meat....
Following the outbreak of COVID-19, the World Health Organization recommended prevention measures to minimize the spread of the pandemic. However, strict compliance with prevention measures requires p...
Universal health coverage is vital to the World Health Organization's (WHO's) efforts to ensure access to health as a human right. However, it has been reported that migrants, including both internati...
The aim of the study was to examine the relationship between social support, marital dissatisfaction, psychological factors, and health-promoting behaviors in pregnant women....
This cross-sectional study was conducted on 1,265 pregnant women who visited the outpatient clinic of a maternity hospital between May and August 2023. The Health Promotion Lifestyle-II Questionnaire ...
Pregnant women had a mean age of 26.46±5.09 years. Multivariate linear regression analysis revealed that there was a positive association between perceived social support and health-promoting behavior...
The present study suggests that stress, anxiety, depression, and marital disaffection are negatively associated with health-promoting lifestyle behaviors, while social support is positively associated...
Homelessness is considered to be a global problem, independent of the material situation of a given country and occurring in most societies around the world....
Assessment of the preferred health behaviors of homeless people....
The study covered 153 men who are homeless and 312 men who are not homeless. The original questionnaire of homeless, and validated the Satisfaction with Life Scale (SWLS), the Health Behavior Inventor...
On average, the homeless men assessed their health at 6.0 ± 2.7 points, and the non-homeless at 7.8 ± 2.2 points (...
The level of the presented health behaviors showed statistically significant diversification with all dimensions of the health locus of control, and its internal dimension with age, homelessness phase...
Socioeconomic status-related (SES-related) health disparities are worsening across resource-rich environments, despite increased knowledge about health determinants and inducements for healthful behav...